UCSF Researchers Identify Protein That Slows Brain Aging—and Show How to Reverse It
Key Takeaways
- ▸FTL1 protein accumulates in the aging brain and directly causes cognitive decline by reducing neural connections and suppressing cellular metabolism
- ▸Reducing FTL1 levels in aged mice reversed age-related memory loss and restored brain cell connectivity—marking a true reversal of aging effects, not just prevention
- ▸Metabolic stimulation compounds can block FTL1's harmful effects, suggesting a promising therapeutic avenue for treating age-related cognitive decline
Summary
Researchers at UC San Francisco have identified FTL1, a protein that accumulates with age and drives cognitive decline in the hippocampus, the brain region critical for learning and memory. In studies with mice, elevated FTL1 levels correlated with fewer neural connections and diminished memory performance, while artificially increasing FTL1 in young mice caused their brains to age prematurely. Remarkably, when scientists reduced FTL1 in the hippocampus of aged mice, the animals regained cognitive abilities and showed restored neural connectivity—demonstrating a reversal rather than merely a slowing of age-related impairment. The findings, published in Nature Aging on August 19, suggest that FTL1 works by suppressing cellular metabolism, and that compounds stimulating metabolism could counteract its effects, potentially opening a path to therapies that combat cognitive aging.
Editorial Opinion
This discovery represents a significant advance in aging biology, moving beyond symptom management toward actionable intervention targets. The ability to reverse—rather than merely delay—cognitive decline in aged animals is particularly noteworthy and could reshape how we approach neurodegenerative diseases. If these findings translate to humans, therapies targeting FTL1 could fundamentally change treatment of age-related memory loss and dementia.
